Germany, Switzerland, BeNeLux, ItalyGermany

Finalists termed

16.09.2006

This year, Europe’s most important and most valuable biotech prize, the European BioTechnica Award, will be confered either to Amaxa GmbH, Intercell AG or Genmab A/S. These three companies have been chosen from an international pool of 16 companies which submitted the comprehensive application form. The winner will be announced at a high-class event in Zurich.

Amaxa, Genmab and Intercell are the finalists for the fourth European BioTechnica Award presented by the Deutsche Messe AG (Hannover, Germany). The BioTechnica Award jury will confer the prize at a festive event on October, 12 in the Park Hyatt Hotel in Zurich. “With the prize award ceremony, talks by guest speakers and an informal get-together for all participants, the event creates the perfect business platform for biotech professionals to network and make valuable contacts,“ says Stephan Kühne, member of the board of Deutsche Messe AG. The winner receives a prize to the value of 40,000 euros. Judging criteria are scientific innovation, commercial viability, market relevance, marketing concept and business model. The 2006 jury consists of a number of well-known industry insiders among them Prof. Dr. Peter Stadler (Managing director Artemis Pharmaceuticals GmbH), Dr. Luca Benatti (CEO Newron Pharmaceuticals SPA), Dr. Philippe Pouletty (Honory Chairman France Biotech) and Dr. Karsten Henco (founder Evotec AG and Qiagen NV).
High-class speakers
Talks by distinguished speakers will set the scene for the festive ceremony. “The keynote addresses are sure to stimulate plenty of lively debate at the informal get-together afterwards,” Kühne predicts. The line-up consists of Dr. Annette Schavan (German minister of Education and Research), Dr. Peter Hug (Roche’s Global Head of Pharma Partnering), Jörn Aldag (CEO Evotec AG) and Dr. Hans-Jürgen Leuchs (Board Member Boehringer Ingelheim). The award ceremony follows the Biotech CEO Conference hosted by the German Stock Exchange and DZ BANK AG in Zurich.
Former winners of the price are GPC Biotech AG, Prionics AG and MediGene AG. The European BioTechnica Award is confered every year by the Deutsche Messe AG and a group of partners, among them BIOCOM AG, the publishing house of EuroBiotechNews.
Amaxa GmbH
The company: Amaxa currently employs a workforce of 145 and generated revenues of 16.6 million Euros in 2005. In addition to its headquarters in Cologne/Germany, the company, which was founded in 1998, also operates a facility in Gaithersburg/USA.
The business: Amaxa develops and sells transfection products in the field of non-viral gene-transfer for primary cells and cell lines. The patented Nucleofactor technology is an ex-vivo tool for gene-based medicine. Technologies under development are also suitable for in-vivo gene transfer.
The Management: Rainer Christine (Managing Director), Alexander Müller (Financial Director), Dr. Hans-Günter Brünker (Corp. Development), Wolfgang Kintzel (Marketing & Sales), Dr. Titus Kretzschmar (R&D).
Genmab A/S
The company: Genmab currently employs a workforce of 220 and generated revenues of 13.2 million euros in 2005. Genmab runs several operations in Europe and the United States and is listed at the Copenhagen Stock Exchange.
The business: Genmab develops human antibodies for the treatment of cancer, infectious diseases and rheumatoid arthritis and runs six clinical programs. The company has closed several alliances with partners, among them Amgen, Serono and Roche. In 1998 Genmab was spun-off from Medarex Inc. to commercialize the UltiMAb® platform.
The Management: Lisa Drakeman (CEO), Claus Juan Møller-San Pedro (COO), Bo Kruse (CFO), Annarie Lyles (Business development), Jan van de Winkel (CSO).
Intercell AG
The company: Intercell employs a workforce of 160 and generated revenues of 8.5 million euros in 2005. The company, founded in 1998, runs an in-house GMP-facility in Livingston/Scotland, in addition to its headquarters in Vienna. In early 2005, Intercell listed at the Vienna stock exchange and was the best performing biotech IPO in Europe.
The business: Intercell develops antigens and immunizers (adjuvants), which are derived from its proprietary technology platforms. Novartis recently bought a 6.1% stake in Intercell and received the co-commercialization rights for the company‘s lead product, a Japanese Encephalitis vaccine in phase III.
The Management: Gerd Zettlmeissl (CEO), Alexander von Gabain (CSO), Werner Lanthaler (CFO)

GermanyGermany

07.03.2012

The first of February marked a milestone for Leverkusen-based Bio­frontera AG in more ways than one. It was the first day that Ameluz, the firm’s first approved product, could be sold in German pharmacies. It was also the date...

GermanyGermany

07.03.2012

Darmstadt – German pharmaceutical and chemical company Merck KGaA has set a downbeat tone for 2012. CEO Karl-Ludwig Kley said the recently launched cost-cutting programme and tough economic conditions will weigh on profits this...

GermanyGermany

05.03.2012

Mainz/Leuna – Two biotech concepts were amongst the winners of the recent third round of the Excellence Cluster initiative, which is funded by the German Ministry for Research. In Mainz the champagne corks popped especially loud...

GermanyGermany

05.03.2012

German Merck KGaA has closed a licencing agreement with US-based Threshold Pharmaceuticals Inc. The cooperation centres around the hypoxia­-activated drug TH-302, which is currently being studied in a global Phase III study....

GermanyGermany

29.02.2012

Munich – Looking back with satisfaction and bent on a prize for good behaviour, German biopharmaceutical company Wilex AG reported yesterday on the fiscal year 2011 and outlined the shores in sight. The 2011 total revenue was...

GermanyGermany

17.02.2012

Brussels – European cartilage researchers intensify their cooperation. The 'gristle network' comprises scientists from Belgium, France, Germany and Luxembourg. Its members plan to meet regularly to exchange views and information...

27.01.2012

Thousand Oaks/Munich - Bling bling for blinatumomab. It is a compliment for the European life sciences scene and sad news at the same time. Amgen Inc., the world's largest biotechnology company, agreed to buy Micromet Inc., an...

GermanyGermany

20.01.2012

Martinsried - SHELTER is responsible for the fact that the stocks of 4SC behaved like a rodeo horse on Thursday. The shares rose in several stages up to 63%, only to settle at a mere 43% rise at the end of the day. SHELTER is a...

GermanyGermany

17.01.2012

Ludwigshafen – BASF Plant Science GmbH, the agrochemistry and biotech arm of the world-largest chemistry company, thinks that it has outstayed its welcome in Europe. Over the next two years, most of the green biotechnology...

GermanyGermany

10.01.2012

Munich - It is the accolade for Micromet. The German company, which is listed on the U.S. stock exchange, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the renowned US...

Displaying results 1 to 10 out of 454

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-germany/article/finalists-termed.html

Image Gallery

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)344.00 GBP12.6%
  • THERAMETRICS (CH)0.11 CHF10.0%
  • ACTIVE BIOTECH (S)35.60 SEK9.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • GENFIT (F)22.42 EUR-8.1%
  • BAVARIAN NORDIC (D)13.63 EUR-6.4%

TOP

  • BIOTECH PHARMACON (N)19.00 NOK73.5%
  • WILEX (D)0.81 EUR42.1%
  • E-THERAPEUTICS (UK)28.00 GBP40.0%

FLOP

  • CYTOS (CH)0.16 CHF-94.1%
  • BIONOR PHARMA (N)2.17 NOK-45.7%
  • IMMUNICUM AB (S)16.40 SEK-36.9%

TOP

  • SILENCE THERAPEUTICS (UK)257.25 GBP6174.4%
  • IXICO (UK)66.50 GBP737.5%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.16 CHF-96.1%
  • EVOCUTIS (UK)0.22 GBP-91.8%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 23.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper